干旱区生态环境知识资源中心(Arid): T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy

Arid

DOI	10.6004/jnccn.2021.7097
	T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy
	Kumar-Sinha, Chandan; Sahai, Vaibhav
通讯作者	Sahai, V (corresponding author)，Univ Michigan, Div Hematol & Oncol, Dept Internal Med, Rogel Canc Ctr, 1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.
来源期刊	JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
ISSN	1540-1405
EISSN	1540-1413
出版年	2022
卷号	20 期号:2 页码:203-214
英文摘要	Patients with advanced hepatocellular or biliary cancers have a dismal prognosis with limited efficacy from standard systemic therapies. The benefit of precision medicine has so far been limited to a subset of biliary cancers, including FGFR rearrangements; hotspot mutations in IDH1/2, BRAF, and BRCA1/2; and other rare alterations. In contrast, hepatocellular carcinoma, an inflammation-driven cancer with an immune-infiltrated microenvironment, provides a promising opportunity for immunotherapy, compared with the highly desmoplastic immune desert or excluded stromal microenvironment in biliary cancers. The immune contexture in hepatobiliary cancers is mostly immunosuppressive, protumorigenic, and exhausted, which together with low tumor mutation burden and decreased neoantigens provides challenges for immunotherapy. A better understanding of the spatiotemporal profile of T cells within the tumor microenvironment and the dynamic interplay of immune modulators in the context of standard or experimental therapies is crucial to define additional markers of response and design evidence-based combinatorial regimens. This review considers recent literature in this area and highlights promising leads and emerging trends.
类型	Review
语种	英语
开放获取类型	Bronze
收录类别	SCI-E
WOS记录号	WOS:000753513600015
WOS关键词	HEPATOCELLULAR-CARCINOMA ; PHASE-II ; CHOLANGIOCARCINOMA ; CHECKPOINT ; THERAPY ; IDENTIFICATION ; PEMBROLIZUMAB ; ACTIVATION ; INHIBITION ; MUTATIONS
WOS类目	Oncology
WOS研究方向	Oncology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/376438
作者单位	[Kumar-Sinha, Chandan] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Kumar-Sinha, Chandan] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Sahai, Vaibhav] Univ Michigan, Div Hematol & Oncol, Dept Internal Med, Ann Arbor, MI 48109 USA; [Sahai, Vaibhav] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA
推荐引用方式 GB/T 7714	Kumar-Sinha, Chandan,Sahai, Vaibhav. T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy[J],2022,20(2):203-214.
APA	Kumar-Sinha, Chandan,&Sahai, Vaibhav.(2022).T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy.JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK,20(2),203-214.
MLA	Kumar-Sinha, Chandan,et al."T-Cell Subsets as Potential Biomarkers for Hepatobiliary Cancers and Selection of Immunotherapy Regimens as a Treatment Strategy".JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK 20.2(2022):203-214.